Clinical Trials | December 30, 2025
Edgewise Therapeutics reports positive updates from HCM drug EDG-7500
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
Harbour BioMed brings advanced antibody discovery platforms to the table
Singlera and Pure Medical will team up with local universities, hospital networks, and national healthcare systems across Western Europe for research studies
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
Intas becomes the first and only company in India to offer IVF and gynecology therapies with needle-free injections
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
Indian Pharmacopoeia is now recognised in 19 countries, reflecting growing international confidence in India’s regulatory and scientific capabilities
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
BBIL will guarantee production and supply of MTBVAC to more than 70 countries across Africa and Southeast Asia
Subscribe To Our Newsletter & Stay Updated
